Thermo Fisher in talks to buy Patheon: Bloomberg
Tweet
Share
E-mail
Traders work at the post where shares of Patheon NV is traded on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 21, 2016. REUTERS/Brendan McDermid
Get Alerts TMO Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.4%
EPS Growth %: +6.7%
Join SI Premium – FREE
(Reuters) - Scientific instruments maker Thermo Fisher Scientific Inc (NYSE: TMO) is in talks to buy Patheon NV (NYSE: PTHN), Bloomberg reported late on Sunday.
Thermo Fisher and Patheon could not be reached for comment outside regular business hours.
An agreement between Thermo Fisher and the Dutch drug ingredients maker could be reached as early as this week, Bloomberg reported, citing people with knowledge of the matter.
The discussions could still falter, and there's no certainty a deal will be reached, Bloomberg added. https://bloom.bg/2qirdlR
Thermo Fisher has seen its stock rise over 21 percent in 2017, bringing its market value to about $67.1 billion, according to Thomson Reuters data.
Shares of Patheon have fallen about 9.4 percent this year, valuing the company at about $3.8 billion.
(Reporting by Ismail Shakil in Bengaluru; Editing by Sunil Nair)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Varonis Said To Weigh Sale After Takeover Interest - Bloomberg
- Coursera holds post-merger modeling call after Udemy acquisition
- Galaxy Digital invests in Digital Prime Technologies' Tokenet platform
Create E-mail Alert Related Categories
Mergers and Acquisitions, Reuters, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
